Teduglutide - Shire

Drug Profile

Teduglutide - Shire

Alternative Names: ALX-0600; Gattex; Revestive

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda Pharmaceuticals International GmbH
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 10 Sep 2018 Shire initiates enrolment in a phase III trial for Short Bowel Syndrome in Japan (NCT03663582)
  • 06 Aug 2018 Phase-III clinical trials in Short bowel syndrome (In infants) in United Kingdom (SC) (NCT03571516)
  • 05 Jul 2018 Phase-III clinical trials in Short bowel syndrome (In infants) in Finland (SC) (EudraCT2017-003606-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top